Status:
RECRUITING
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
Lead Sponsor:
Riboscience, LLC.
Conditions:
Advanced Unresectable Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic gua...
Detailed Description
In this Phase 2a study, participants must have advanced, unresectable HCC confirmed by radiology, histology or cytology. Participants must be eligible to receive the STRIDE regimen as first line thera...
Eligibility Criteria
Inclusion
- At least 18 years of age on the day of signing informed consent.
- Male and female participants with advanced, unresectable HCC who are eligible to receive STRIDE regimen as first line therapy.
- Willing to submit a pre-treatment tissue sample (archival or fresh tissue if archival is not available).
Exclusion
- BCLC stage D disease at the time of screening or prior to first dose of RBS2418.
- Child-Pugh class equal or higher than B8 at the time of screening or within 7 days prior to the first dose of study treatment.
- Eligible for curative treatments (e.g., surgical resection, liver transplantation, or local ablation).
- Evidence of rapid progression on prior therapy resulting in rapid clinical deterioration.
Key Trial Info
Start Date :
January 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT07175441
Start Date
January 1 2026
End Date
August 1 2027
Last Update
December 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins
Baltimore, Maryland, United States, 21218